ADXN

Addex Therapeutics Ltd is a clinical-stage pharmaceutical company that develops and commercializes orally available small molecule drugs known as allosteric modulators, targeting neurological disorders. Its product pipeline includes candidates such as Dipraglurant for post-stroke and traumatic brain injury recovery, and ADX71149 for substance use disorder and chronic cough. The company focuses on research and development in the field of allosteric modulation to address various neurological conditions.